Sutro Biopharma

company

STRO Nasdaq ISIN US8693671021 SEC CIK 1382101 LEI 5493005U6P15VD25P851
Follow Sutro Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $9.1M −6.1% vs same quarter last year
Net income −$31.5M +44.6% vs same quarter last year
EPS, diluted −$1.90 +71.5% vs same quarter last year
Operating cash flow −$22.5M +41.2% vs same quarter last year
Revenue by quarter
$14.8M
$17.4M
$63.7M
$9.7M
$11.6M
$14.5M
$9.8M
$9.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100M$200MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$102.5M−$191M
FY24$62M−$227M
FY23$153.7M−$107M
FY22$67.8M−$119.2M
FY21$61.9M−$105.5M
FY20$42.7M−$32.1M
FY19$42.7M−$119.2M
FY18$38.4M−$35.3M
FY17$51.7M−$19.7M
FY16$59.7M$1.7M
FY15--
MarginsShare of revenue
  • Operating margin
  • Net margin
−400%−300%−200%−100%0%100%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−154.5%−186.4%
FY24−384.3%−365.9%
FY23−58.1%−69.6%
FY22−190.3%−175.9%
FY21−159.2%−170.6%
FY20−166.3%−75.2%
FY19−129.8%−278.9%
FY18−96.9%−91.9%
FY17−37.2%−38.1%
FY162.3%2.8%
FY15--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0$20MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18$11.1M
FY17−$40.4M
FY16−$17.5M
FY15-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Sutro Biopharma
  • Healthcare median
−400%−300%−200%−100%0%100%FY15FY17FY19FY21FY23FY25
Show the numbers
YearSutro BiopharmaHealthcare median
FY25−186.4%−30.6%
FY24−365.9%−47%
FY23−69.6%−58%
FY22−175.9%−80.4%
FY21−170.6%−71.8%
FY20−75.2%−62.2%
FY19−278.9%−46.2%
FY18−91.9%−49.6%
FY17−38.1%−45.9%
FY162.8%−36%
FY15-−37.8%